Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | IL6 | P05231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492342 | 1.00 | NFKB1 (0.56) | NFKB1NFE2L2MAOBTRPA1BACE1 | |
| SCHEMBL6418952 | 0.86 | MAOB (0.52) | NFKB1NFE2L2MAOBTRPA1BACE1 | |
| SCHEMBL27463466 | 0.83 | NFKB1 (0.57) | NFKB1MAOBBACE1APPP4HB | |
| SCHEMBL3244255 | 0.81 | NFKB1 (0.48) | NFKB1NFE2L2MAOBBACE1P4HB | |
| SCHEMBL18002839 | 0.81 | NFKB1 (0.50) | NFKB1NFE2L2MAOBBACE1APP | |
| SCHEMBL5493270 | 0.81 | NFE2L2 (0.64) | NFE2L2MAOBTRPA1RAB9A | |
| SCHEMBL20283098 | 0.81 | NFKB1 (0.46) | NFKB1NFE2L2MAOBAPPTNF | |
| SCHEMBL5493262 | 0.81 | NFE2L2 (0.64) | NFE2L2MAOBTRPA1RAB9A | |
| SCHEMBL17068273 | 0.81 | NFKB1 (0.84) | NFKB1NFE2L2MAOBBACE1P4HB | |
| SCHEMBL241267 | 0.79 | NFE2L2 (0.50) | NFE2L2MAOBTRPA1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3280402-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | Biomendics LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2016164531-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | BioMendics, LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | NFKB1 25/4885NFE2L2 696/4885MAOB 961/4885 |
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | NFKB1 1817/4885NFE2L2 1434/4885MAOB 3743/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | NFKB1 1807/4885NFE2L2 1303/4885MAOB 3725/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | NFKB1 18/4885NFE2L2 68/4885MAOB 1359/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | NFKB1 26/4885NFE2L2 63/4885MAOB 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.